Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 1
2016 3
2017 5
2018 2
2019 2
2020 2
2021 3
2023 2
2024 1
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer.
Ekstrom TL, Rosok RM, Abdelrahman AM, Parassiadis C, Manjunath M, Dittrich MY, Wang X, Kutschat AP, Kanakan A, Rajput A, Schacherer N, Lukic T, Carlson DM, Thiel J, Kopp W, Stroebel P, Ellenrieder V, Gaedcke J, Dong M, Najafova Z, Truty MJ, Hessmann E, Johnsen SA. Ekstrom TL, et al. Among authors: najafova z. Gut. 2025 Jun 6;74(7):1112-1124. doi: 10.1136/gutjnl-2024-334374. Gut. 2025. PMID: 39884837
GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.
Latif MU, Liu X, Bockelmann A, Huhnold L, Schmidt GE, Klein L, Zhao X, Conradi LC, Conrads K, Weber AL, Mercan S, Reutlinger K, Paul A, Najafova Z, Johnsen SA, Bonilla Del Rio Z, Penz F, Todorovic J, Bastians H, Beissbarth T, Sax U, Ashry R, Krämer OH, Hessmann E, Schneider G, Stroebel P, Bogeski I, Singh SK, Ellenrieder V. Latif MU, et al. Among authors: najafova z. Gut. 2026 Jul 8;75(8):1520-1533. doi: 10.1136/gutjnl-2025-336227. Gut. 2026. PMID: 41475977 Free article.
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival.
Ekstrom TL, Dai Z, Thiel J, Kanakan A, Saha BJ, Manjunath M, Schacherer N, Bousounis P, Siegler EL, Abdelrahman AM, Souto Y, Essmann F, Najafova Z, Beyes S, Truty MJ, Dong M, Johnsen SA. Ekstrom TL, et al. Among authors: najafova z. Sci Adv. 2026 Mar 20;12(12):eaea2106. doi: 10.1126/sciadv.aea2106. Epub 2026 Mar 18. Sci Adv. 2026. PMID: 41849608 Free PMC article.
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer.
Hamdan FH, Abdelrahman AM, Kutschat AP, Wang X, Ekstrom TL, Jalan-Sakrikar N, Wegner Wippel C, Taheri N, Tamon L, Kopp W, Aggrey-Fynn J, Bhagwate AV, Alva-Ruiz R, Lynch I, Yonkus J, Kosinsky RL, Gaedcke J, Hahn SA, Siveke JT, Graham R, Najafova Z, Hessmann E, Truty MJ, Johnsen SA. Hamdan FH, et al. Among authors: najafova z. Gut. 2023 Jun;72(6):1174-1185. doi: 10.1136/gutjnl-2022-328154. Epub 2023 Mar 8. Gut. 2023. PMID: 36889906 Free PMC article.
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
Kutschat AP, Hamdan FH, Wang X, Wixom AQ, Najafova Z, Gibhardt CS, Kopp W, Gaedcke J, Ströbel P, Ellenrieder V, Bogeski I, Hessmann E, Johnsen SA. Kutschat AP, et al. Among authors: najafova z. Cancer Res. 2021 Jun 1;81(11):2943-2955. doi: 10.1158/0008-5472.CAN-20-2874. Epub 2021 Jan 12. Cancer Res. 2021. PMID: 33436389 Free PMC article.
CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A, Dickmanns A, Najafova Z, Johnsen SA, Dobbelstein M. Sriraman A, et al. Among authors: najafova z. Cell Death Dis. 2018 Sep 11;9(9):918. doi: 10.1038/s41419-018-0968-0. Cell Death Dis. 2018. PMID: 30206211 Free PMC article.
Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma.
Wang X, Kutschat AP, Aggrey-Fynn J, Hamdan FH, Graham RP, Wixom AQ, Souto Y, Ladigan-Badura S, Yonkus JA, Abdelrahman AM, Alva-Ruiz R, Gaedcke J, Ströbel P, Kosinsky RL, Wegwitz F, Hermann P, Truty MJ, Siveke JT, Hahn SA, Hessmann E, Johnsen SA, Najafova Z. Wang X, et al. Among authors: najafova z. Mol Cancer Res. 2023 Sep 1;21(9):881-891. doi: 10.1158/1541-7786.MCR-22-0916. Mol Cancer Res. 2023. PMID: 37279184 Free PMC article.
24 results